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ABSTRACT: Pharmaceutical nanosuspensions are formed
when drug crystals are suspended in aqueous media in the
presence of stabilizers. This technology oﬀers a convenient way
to enhance the dissolution of poorly water-soluble drug
compounds. The stabilizers exert their action through electro-
static or steric interactions, however, the molecular requirements
of stabilizing agents have not been studied extensively. Here,
four structurally related amphiphilic Janus-dendrimers were
synthesized and screened to determine the roles of diﬀerent
macromolecular domains on the stabilization of drug crystals.
Physical interaction and nanomilling experiments have sub-
stantiated that Janus-dendrimers with fourth generation hydro-
philic dendrons were superior to third generation analogues and
Poloxamer 188 in stabilizing indomethacin suspensions. Contact angle and surface plasmon resonance measurements support
the hypothesis that Janus-dendrimers bind to indomethacin surfaces via hydrophobic interactions and that the number of
hydrophobic alkyl tails determines the adsorption kinetics of the Janus-dendrimers. The results showed that amphiphilic Janus-
dendrimers adsorb onto drug particles and thus can be used to provide steric stabilization against aggregation and
recrystallization. The modular synthetic route for new amphiphilic Janus-dendrimers oﬀers, thus, for the ﬁrst time a versatile
platform for stable general-use stabilizing agents of drug suspensions.
1. INTRODUCTION
Many newly developed active pharmaceutical ingredients
(APIs) are poorly soluble in water as well as in biological
ﬂuids. Drug nanocrystals in which the particle size of a drug is
nanosized to increase its surface area were developed to
circumvent this solubility issue.1 Media milling is currently a
widely used method to reduce particle size, which in turn
increases the APIs’ surface area and the surface-speciﬁc drug
dissolution rate. However, drug nanocrystals tend to form
aggregates or to coalesce due to the Ostwald ripening
phenomenon.2,3 It is postulated that if a dense enough steric
stabilizer layer is formed around drug particles dispersed in
solution, the formation of van der Waals forces is hindered and
the drug particles remain separated from each other. Hence,
drug crystals must be stabilized using a polymer or a surfactant
coating that increases repulsive electrostatic interactions, steric
strain, and shelf life during storage. The advantage of stabilized
drug nanocrystals is that the majority of the formulated
product consists of drug material, which is not easily achievable
with other types of carrier-systems.4 Moreover, the use of
stabilized nanocrystals improves drug bioavailability by other
means, for example, via enhanced mucoadhesion and eﬄux
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inhibition.5 Screening methods for the production and
subsequent analyses of nanosuspensions are limited,6 and few
pharmaceutically accepted excipients are currently utilized as
stabilizers.7 Amphiphilic copolymers in which the diﬀerent
domains of the polymer have aﬃnity toward either the
adsorbent (particle surface) or dispersion medium have been
found to be suitable steric stabilizers. Among the various
copolymers used for drug particle stabilization, Poloxamer 188,
a nonionic triblock copolymer composed of a hydrophobic
polyoxypropylene chain edged by two hydrophilic polyoxy-
ethylene chains, is one of the most widely used and studied.
Dendrimers are a class of well-deﬁned, periodically branched
macromolecules8−10 in which a recurrent branching of the
building blocks originating from a core results in a core−shell
structure.11,12 Intrinsic structural features of dendrimers allow
for the covalent conjugation of drug molecules or complex-
ations through multivalent noncovalent interactions.13−15
Amphiphilic Janus-dendrimers (JDs)16−19 are essentially
synthetic surfactants, which combine hydrophilic and hydro-
phobic dendritic domains into a single macromolecule. Their
structural versatility is demonstrated by the diﬀerent families of
JDs17,20−24 and Janus-glycodendrimers.25−28 When injected
from dilute organic solutions into aqueous or biological media,
some JDs readily self-assemble into bilayered, vesicle-like
structures, that is, dendrimersomes17,29 and glycodendrimer-
somes,30−33 or other complex architectures.17,34,35 The shape
and size of these assemblies can be controlled and even
predicted using existing semiempirical models.36−38 Several
dendrimer compositions39 have been employed in diverse
biomedical applications,40 for example, as a coating for 3D
DNA nanostructures for improved stability against endonu-
cleases,41 as antibacterial agents with minimal eukaryotic cell
toxicity,42 as sealants for wound closure,43 and as supra-
molecular hydrogels for sustained drug release.44
Here we hypothesized that high-generation amphiphilic JDs,
which have a high density of hydroxyl-terminated bis-MPA
dendrons per molecule while at the same time exhibit
hydrophobic dodecyloxy chains, could be prime candidates
for stabilizing colloidal drug suspensions through steric
stabilization. The aim of the study was to investigate if high-
generation JDs could be eﬀectively used to stabilize drug
suspensions of the poorly water-soluble drugs indomethacin
and itraconozale and compare their performance with
Poloxamer 188. The study describes for the ﬁrst time the
mechanisms by which amphiphilic JDs stabilize pharmaceutical
drug suspensions and the inﬂuence of the number of
hydrophobic alkyl tails in the adsorption kinetics of the JDs
to drug crystals in suspension.
2. EXPERIMENTAL SECTION
Materials. All reagents and solvents used in the synthesis of JDs
were obtained from commercial sources (Acros, Aldrich, Fisher, and
Rathburn; reagent grade) and were used without prior puriﬁcation.
Dry dichloromethane (CH2Cl2) and tetrahydrofuran (THF), which
were used for the synthesis of intermediate compounds, were
obtained from a solvent drier (MB-SPS-800, neutral alumina;
MBraun, Germany) and used when necessary. The deuterated
DMSO-d6 for NMR analysis was purchased from Euriso-top (Saint
Aubin Cedex, France). Propargyl-modiﬁed bis-MPA dendrons (G1−
G4) were synthesized according to Wu et al. (3, 5, 7, 9
Supplementary Scheme S1).45 Percec-type hydrophobic G1 azide
dendrons were prepared according to Nummelin et al. (14a, b
Supplementary Scheme S2).44,46 Amphiphilic JDs 3,4-G3 and 3,4,5-
G3 (Figure 1) were prepared as described previously.44 The
characterization data were in agreement with the literature.
Itraconazole (Derivados Quimicos Fine Chemicals, Spain) and
indomethacin (Orion Pharma, Finland) were used as model drugs.
Poloxamer 188 (BASF, Germany) was used as a model stabilizer
(positive control). Potassium hydroxide and acetic acid (Sigma-
Aldrich, Germany) were used to make the acetic acid buﬀer at pH
5.00. Ethanol (99.5%; Altia, Finland) was used as a solvent for
indomethacin during the ultraviolet (UV) spectroscopy measure-
ments. Magnesium stearate (Orion Pharma, Finland) was used as a
lubricant during the tableting procedure for the contact angle
measurements. Ultrapure water (18.2 MΩ·cm) was obtained from
Millipore Elix 5 equipment (Merck, France).
Figure 1. Chemical structures and short notation of the Janus-dendrimers evaluated in this study.
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Synthesis and Characterization of Janus-Dendrimers.
General Procedure. The azide dendron 14a or 14b (1.05 equiv),
G3 or G4 bis-MPA-alkyne 7 or 9 (1 equiv), and sodium L-ascorbate
(20 mol %) were dissolved in THF in a vial. Cu(II)SO4 (10 mol %)
was dissolved in H2O and added to the reaction. The mixture was
stirred for 5 min at RT before DMSO was added. The mixture was
stirred 24 h at 60 °C before it was cooled to RT. The crude product
was puriﬁed by ﬂash chromatography on SiO2, aﬀording Janus-
dendrimers as oﬀ-white solids (see Supporting Information Schemes
S1−S4 for details).
Nuclear Magnetic Resonance (NMR). 1H NMR (400 MHz)
spectra and uniform driven equilibrium Fourier transform (UDEFT,
pulse program: udef t) 13C NMR (100 MHz) spectra were recorded
on a Bruker Avance DPX400 spectrometer equipped with a 5 mm
BBFO probehead. Chemical shifts (δ) were reported in ppm (Figures
S1−S4). The residual protic solvent of DMSO-d6 (
1H, δ 2.50 ppm;
13C, δ 39.50 ppm) was used as the internal reference. Coupling
constants (J) were reported in Hertz (Hz). Heteronuclear 1H-13C
connectivities were determined by adiabatic HSQC experiments
(pulse program: hsqcetgpsisp.2).
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight
Mass Spectrometry (MALDI-TOF). The analyses were carried out
using a Bruker UltraﬂeXtreme MALDI-TOF/TOF mass spectrometer
(Bruker Daltoniks, Bremen, Germany) equipped with a SmartBeam II
laser (355 nm) operating at 2 kHz with a 200 μm raster in reﬂectron
positive mode. FlexAnalysis v3.4 was used to assign molecular isotopic
masses in the 200−4000 Da mass range. 2,5-Dihydroxybenzoic acid
(DHB) mixed in a THF (10 mg mL−1) was used as a matrix. A
concentration of 2 mg mL−1 of the sample in THF was mixed with the
matrix solutions in 1:1 (v/v) ratio and applied to the stainless steel
target plate. Sample droplets were dried under a gentle air stream at
room temperature to obtain small crystals that simpliﬁed ionizaton. A
peptide calibration standard II (Bruker starter kit # 8208241) was
used for calibration.
Thermal Analysis. For each JD, a physical mixture with bulk
indomethacin was prepared by weighing and mixing 20.0 mg of the
bulk drug and 2.0 mg of a solid dendrimer, respectively. The resulting
mixtures, as well as neat JDs and indomethacin, were then subjected
to thermal analysis. Thermal transitions were measured using a
Mettler Toledo 823e (Switzerland) diﬀerential scanning calorimeter
and were processed using STARe software (Mettler Toledo, version
9.00). Samples (3−7 mg) were annealed for 5 min at 25 °C before
they were heated to 190 °C at 10 °C min−1 heating rate. Nitrogen was
used as a purge gas at a 50 mL min−1 ﬂow rate. Thermal transitions as
peak maximas (°C) and enthalpies (kcal mol−1) are reported in
Supporting Information Tables S2 and S3. Indium was used as a
calibration standard both for temperature and enthalpy. Melting
points for the 3,4-G4 and 3,4,5-G4 JDs were taken as the maxima of
the endothermic peaks.
Contact Angle. Aqueous dendrimer solutions (0.4 mg mL−1), an
aqueous poloxamer solution (1.0 mg mL−1), and water were used for
the contact angle measurements. The contact angles were measured
on cylindrical drug compacts produced from 300 mg bulk
indomethacin in an infrared spectroscopy pellet (⌀ 13 mm) by
applying one ton compression for 10 s using an Atlas 15.001 manual
hydraulic press (SPECAC, England). A sample solution droplet
(about 2 μL) was deposited onto an indomethacin compact, and
images were captured once per second for 1 min using a Cam200
Contact Angle Meter (KSV Instruments, Finland) and were processed
using Attension Theta software (Biolin Scientiﬁc, version 4.1.0). The
average and standard deviation of the contact angles are presented as
functions of time.
Surface Plasmon Resonance. The interactions of indomethacin
with 3,4-G4, 3,4,5-G4, and the poloxamer reference were determined
by surface plasmon resonance (SPR) measurements performed using
a 4-channel multiparametric MP-SPR 200 instrument (BioNavis,
Finland) equipped with a 670 nm laser and a peristaltic pump
(Ismatec, Germany). Indomethacin was deposited onto gold SPR
sensor surfaces from aliquots of a saturated indomethacin solution
that was preprepared by shaking indomethacin in ethanol (4 mg
mL−1) overnight. The SPR signal baseline was ﬁrst recorded in pure
water, and the SPR sensograms were obtained by recording the
change in the SPR angle approximately every 5.3 s during 50 μM
aqueous stabilizer solution injection for 15 min (association phase)
and subsequently during pure water injection for at least an additional
15 min (dissociation phase). For comparison, the SPR measurements
were repeated with plain gold sensors alone. The recorded data were
baseline corrected using the background data and were modeled using
Matlab R2014a software (MathWorks, version 8.3.0.532) with an in-
house algorithm that removes measurement disturbances with a
simple input method and optimizes the range of time points to ﬁt the
exponential decay models to the association and dissociation phases.
Manual Milling. Bulk indomethacin or itraconazole (4.0 mg)
were placed in a glass test tube with 3.0 g of zirconium oxide beads (⌀
1 mm), and 1 mL of the aqueous stabilizer solution was used as the
milling medium. The tube was capped, and the bulk drug was
manually milled utilizing vortex-mixing: 60 s continuous milling
periods and 15 s pauses were alternated until the total milling time
reached 6 min. Longer manual milling times were not required for the
screening, as it has been shown that the rate of particle size reduction
decreases during extended milling periods.6
Particle Preparation. The indomethacin suspensions were
manually milled in aqueous dendrimer solutions (0.40 mg mL−1)
and were stored at RT. An aqueous poloxamer solution (1.00 mg
mL−1) was used as the milling medium for the positive controls and
water without excipients was used as the milling medium for the
negative controls. In order to separate any JD aggregates from the
drug particles, all four JD solutions were also subjected to a manual
milling process without indomethacin and were monitored in parallel
with the indomethacin suspensions.
Particle Sizing. Particle size was measured using dynamic light
scattering (DLS). The milled drug suspensions were vortex-mixed for
30 s, diluted 40-fold with water, and brieﬂy mixed again prior to
subjecting the dilutions to the DLS analysis in a disposable plastic
cuvette. Z-average size and PDI were recorded. DLS analyses were
performed at 25 °C using a Zetasizer Nano ZS (Malvern Instruments,
U.K.) equipped with 4 mW He−Ne laser 633 nm and an avalanche
photodiode positioned at 173° to the beam. Instrument parameters
and measurement times were determined automatically. The size was
determined based on an average of 12 measurement runs in triplicate.
Stability Studies. After milling, the suspensions were subjected to
particle size analysis for 4 weeks. During the ﬁrst week, the
repeatability of the milling process was followed with three separately
milled samples. From the second to the fourth week, the particle size
of a single sample was monitored weekly.
Redispersion Studies. For the redispersion studies, two
separately milled suspensions were pooled, and 700 μL of the
suspension was dried on well plates in an oven for 4 d at 40 °C.
Saturated aqueous indomethacin solutions were subsequently
prepared and ﬁltered. The dried samples were dispersed in 700 μL
aliquots of the saturated indomethacin solutions, followed by 3 min of
sonication (35 kHz) prior to subjecting the redispersed suspensions
to particle size analysis.
UV Spectrophotometry. The UV absorption spectra of 40 μg
mL−1 indomethacin in ethanol and 100 μg mL−1 3,4-G4 in water
(Figure S5) were recorded from 190 to 400 nm using a quartz cuvette
and a UV-1600PC spectrophotometer (VWR international, China) to
select wavelengths for subsequent UV determinations. At 318.5 nm,
indomethacin has a local absorbance maximum and the absorbance of
the dendrimer is at minimum. Therefore, this wavelength was selected
for the determination of indomethacin content in solutions with the
dendrimers. Accordingly, the indomethacin content in the milled
suspensions was determined as follows: 10 μL of each suspension was
dissolved in 990 μL of ethanol, and then the indomethacin content of
the solutions was determined using a calibration curve (318.5 nm
wavelength). The drug content in each suspension was calculated
based on triplicate measurements.
At 260.3 nm, indomethacin has high absorbance values and the
dendrimer has a local absorption minimum, whereas at 280.0 nm the
absorbance of indomethacin is reduced and the dendrimer has a local
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absorption maximum. Monitoring absorbance at 260.3 nm allows for
the estimation of indomethacin content that is below the lower limit
of detection at 318.5 nm. In such a case, the inﬂuence of the
dendrimer concentration on the results should be monitored based on
the absorbance values at 280.0 nm. Finally, neither indomethacin nor
the dendrimer absorb light at a 400 nm wavelength. In theory, light
scattering due to particulate matter in the samples can distort the UV
determinations. Thus, the absorbance of each sample was also
measured at a 400.0 nm wavelength.
Saturation Solubility. Bulk indomethacin (10.0 mg) was
weighed into glass vessels, and 1.5 mL of a 12 mM acetate buﬀer
(pH 5.0) was added to the vessels. Next, 0.5 mL of aqueous
dendrimer solution (0.4 mg mL−1), aqueous poloxamer solution (1.0
mg mL−1), or water was added. The vessel was sealed tightly, placed
for overhead shaking in a REAX 2 shaker (Heidolph, Germany) for 24
h at RT, and allowed to stand for 12 h before the solution was ﬁltered
through a 0.2 μm ﬁlter. The absorbance of the ﬁltered solution was
determined at four predeﬁned wavelengths. The indomethacin
content was determined using a UV spectroscopy calibration curve
(260.3 nm). The concentration of indomethacin in the saturated
solution, as well as the absorbance at 280.0 nm were recorded.
Dissolution Rate. Dissolution experiments were conducted with
500 mL of a 12 mM acetate buﬀer (pH 5.0) stirred (50 rpm) using a
DT6 dissolution apparatus (Erweka, Germany) in an ET 15001
(Erweka, Germany) heat bath at 37 °C. Independently milled
indomethacin suspensions were stored at RT for 1 d before subjecting
them to the dissolution experiment. Each measurement with the
suspensions began with placing 500 μL of a vortex-mixed suspension
into the dissolution chamber of the apparatus. The dissolution
experiments with bulk indomethacin began with measuring 2.0 mg of
nonmilled indomethacin powder into the dissolution vessel and
pouring 500 mL of a prewarmed, 12 mM acetate buﬀer (pH 5.0) into
the vessel at the start of the experiment. The dissolution process was
monitored as a function of time by taking 1 mL aliquots from the
dissolution media at deﬁned time points. The indomethacin content
in the samples was determined using a UV spectroscopy calibration
curve (318.5 nm). The extent of dissolution was calculated for the
dissolution samples at each time point, and the averages and standard
deviations of the dissolution proﬁles were calculated and reported.
3. RESULTS AND DISCUSSION
Screening Study Design. To validate the manual milling
methodology for the screening studies, indomethacin was
media-milled in an aqueous Poloxamer 188 solution (positive
control) and in water (negative control). For the manual
milling method, the initial Z-average size was 1231 nm for the
positive control and 814 nm for the negative control. The
positive control was selected on the basis of earlier studies:
when indomethacin is mechanically milled using poloxamer as
the stabilizer, monodisperse submicron drug particles are
obtained.47 The presence of poloxamer in the samples should
not inﬂuence the DLS results by changing the viscosity of the
dispersant, as a 2000-fold concentration increase only changes
the viscosity of the aqueous solution to 1.26 mPas48 from
about 0.89 mPas (the viscosity of plain water at RT).
Therefore, the diﬀerence in the initial sizes of the controls
should reﬂect a successful adsorption of poloxamer onto the
indomethacin particles or a slightly reduced milling eﬃciency.
After 3 weeks of storage at RT, the Z-average size of the
positive control only showed a moderate increase (+121 nm)
compared to the negative control (+3667 nm). Small-scale
manual milling reduced the size of the particles in
indomethacin suspensions, and the suspensions were success-
fully stabilized by the poloxamer (positive control). Hence, it
was concluded that this experimental approach could be used
in screening studies involving JDs.
A preliminary screening of JDs with two diﬀerent drugs
(indomethacin and itraconazole) was conducted to conﬁrm
their particle size-stabilizing eﬃciency and the proper
concentration of dendrimer solutions, as well as to select the
model drug for further investigations. Three diﬀerent
concentrations of 3,4-G4 were used in the screenings, as
follows: low (0.04 mg mL−1), medium (0.10 mg mL−1), and
high (0.40 mg mL−1). Additionally, poloxamer was also
investigated as a stabilizer for both indomethacin and
itraconazole at a concentration of 1.0 mg mL−1 to provide a
benchmark for the JDs. Manually milled indomethacin and
itraconazole suspensions were stored at 4 °C for 138 and 144
days, respectively. After four months of storage, all the
suspensions were subjected to particle size analysis, and as a
conclusion indomethacin suspensions showed smaller Z-
average size and narrower size distribution than itraconazole
suspensions and poloxamer-stabilized suspensions (Figure S6).
The observed low reproducibility of this screening method,
especially in the case of itraconazole, is assumed to be due to
the manual milling procedure and the hardness of the drug
compound. Mechanization of the process, together with longer
milling times, is expected to decrease the variability of the
results. The conservation of the smaller Z-average for extended
periods of time is one of the hallmarks of successful drug
particle stabilization.5 Poloxamer was found to prevent
agglomeration during the four month storage and under our
experimental conditions the JDs performed equally or better
with only a fraction of the concentration required for
poloxamer. This is thought to be due to the high density of
hydroxyl-terminated bis-MPA dendrons per molecule which
leads to a strong physical barrier on the particles’ surface that
hinders the attractive van der Waals’ forces between particles.
Furthermore, the mechanical milling procedure of bulk
indomethacin required less time and material in contrast to
bulk itraconazole, which required at least two grams of
material.49 Therefore, indomethacin was selected as the sole
model drug to be further studied with the four diﬀerent types
of JDs, namely G3 and G4 both with 3,4- and 3,4,5-branching
(Table S1). The data collected from the preliminary screenings
led us to choose a 1:10 dendrimer-to-drug mass-ratio for
preparing the forthcoming indomethacin suspensions by
manual milling.
Interaction Studies. The thermal behavior of the pristine
JDs and the JD-indomethacin physical mixtures (JD/IND =
1:10) were analyzed using diﬀerential scanning calorimetry
(DSC) to discern physical interactions and the chemical
compatibility of the mixtures. All dendrimers, except 3,4-G3,
displayed a broad melting transition (>6 kcal mol−1) preceded
by one or two weaker endothermic transitions (Figure 2, Table
S2), which most likely indicate a small-scale structural
rearrangement (solid-state phase transition) of the dendritic
branches. The 3,4,5-branched JDs generally showed about 20
°C higher melting points than their 3,4-branched analogues. In
the case of 3,4-G3, due to its amorphous nature a glass
transition (ΔCp = 0.08 kcal mol
−1 K−1) was observed at 94.3
°C accompanied by a structural relaxation (enthalpic) peak on
top of it. Moreover, 3,4,5-G3, and 3,4,5-G4 dendrimers
exhibited liquid crystal phases, as weak endothermic
isotropization transitions were observed in the DSC curves at
169.8 and 152.8 °C, respectively. Neat indomethacin showed
only a sharp melting transition (Tm) at 160.4 °C (Te = 159.3
°C), which corresponds with the melting temperature of the
crystalline γ-form of indomethacin.50
Biomacromolecules Article
DOI: 10.1021/acs.biomac.8b00931
Biomacromolecules 2018, 19, 3983−3993
3986
Physical mixtures of the JDs and indomethacin systemati-
cally exhibited the same endothermic transitions correspond-
ing with those previously observed for their individual
components, as evidenced by the DSC curves (Figure 2 and
Table S3). Generally, the endotherms of the dendrimer
components become somewhat more diﬃcult to observe in
the scans as the weight fraction of the JDs, and consequently,
the magnitude of transitions, became only 1:10 that of pristine
JDs. Nonetheless, only the isotropization peak of the LC phase
of 3,4,5-G4 (152.8 °C) was missing in the DSC curve but was
likely buried underneath the broadened indomethacin melting
peak and thus not evident. Predictably, the melting transitions
of indomethacin showed somewhat broader melting ranges
and small downward shifts in peak maxima (1.0−1.5 °C). This
phenomenon is caused by the well-known “impurity eﬀect”,
which occurs when small amounts of a foreign substance are
added to a pure component, and it is commonly reported for
physical mixtures of stabilized drugs as well. For example, the
shift from 165.0 to 133.6 °C (50:50) and 112.3 °C (30:70) has
been reported for indomethacin and poloxamer mixtures.51 In
conclusion, the absence of major discrepancies in the thermal
events conﬁrms that JDs and indomethacin do not show
eutectic melting behavior, cocrystal formation, or induction of
polymorphs because indomethacin remains in crystalline γ-
form. In addition, the overall crystallinity of the JD-
indomethacin mixtures remained unchanged after mixing.
As discussed by Bakatselou et al.,52 surfactants may promote
the wetting of drug particles, thereby increasing the drug
dissolution rate. Therefore, contact angle measurements of
aqueous solution droplets on compressed indomethacin
surfaces were carried out to investigate the wettability of the
drug when in contact with diﬀerent JDs and the poloxamer
(Figure 3). The procedure mimics the media milling
conditions in which solid drug particles are dispersed in
aqueous stabilizer solutions. The measured contact angles of
water and the aqueous poloxamer solution were in agreement
with the literature data.47 The contact angles measured
between the dendrimer solutions and indomethacin were
consistently higher than the contact angles between poloxamer
solution and indomethacin. In general, the contact angles
between aqueous dendrimer solutions and indomethacin were
comparable to the contact angle values between plain water
and indomethacin at the end of the experiment. In contrast,
the contact angle between the 3,4-G3 solution and
indomethacin was slightly lower than the contact angle
between water and indomethacin. A careful examination of
the contact angles as a function of time revealed that the
contact angles of samples that contained 3,4-G3 and 3,4-G4
JDs decreased faster than the contact angle values between
water and indomethacin. The contact angles of 3,4,5-G3 and
3,4,5-G4 followed the contact angle values between water and
indomethacin throughout all experiments. Studies investigating
hydrocarbon materials have suggested that contact angles
between liquids and coated solid materials reﬂect the
properties of the solvent-exposed chemical groups of the
coatings rather than those of the bulk solid.53,54 Accordingly, if
a drop of an aqueous solution of a stabilizer has a lower contact
angle on the indomethacin surface than a drop of water, a
decrease in the contact angle value due to the presence of
dissolved stabilizers should reﬂect reductions in the solid−
liquid and liquid−vapor interfacial energies caused by the
adsorption of the materials onto these interfaces. As the
dendrimers with fewer aliphatic chains in the hydrophobic
dendron (3,4-G3 and 3,4-G4, as opposed to 3,4,5-G3 and
3,4,5-G4) displayed some surface-active characteristics under
these experimental conditions, it is assumed that these
Figure 2. DSC curves [10 °C min−1] of Janus dendrimers (colored
solid line), indomethacin (black dashed line), and physical mixtures of
Janus dendrimers (10 wt %) and indomethacin (colored dashed line).
Transition temperatures are marked in each curve as peak maxima
[°C].
Figure 3. Contact angle of a drop of aqueous (A) 3,4-G3, (B) 3,4,5-
G3, (C) 3,4-G4, and (D) 3,4,5-G4 solution (0.4 mg mL−1 deposited
onto an indomethacin tablet; solid line ± colored area), aqueous
poloxamer solution (1.0 mg mL−1; line with long dashes ± light gray
area), and water (line with short dashes ± dark gray area). Chemical
structures are abbreviated with colored text. The solid line curves are
the average of three separate measurements ± standard deviation,
represented as the colored area.
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dendrimers enable drug particle wetting to a greater extent
which could aid the dissolution process. However, none of the
dendrimers achieved the same reduction in contact angle as the
poloxamer.
The interactions between the drug and dendrimers were
further studied using MP-SPR to identify the solid−liquid
interface interactions independent of the interactions at the
liquid−air and solid−air interfaces. In general, G4 JDs and
poloxamer adsorbed onto plain gold (Figure 4A−C) and
indomethacin surfaces (Figure 4D−F). The injection of G3
JDs did not result in detectable changes in the SPR peak
angular positions (data not shown). The G4 JDs showed very
little or no desorption from plain gold or indomethacin
surfaces (Figure 4A,B and D,E), whereas poloxamer clearly
desorbed from the surfaces (Figure 4C,F). Because the SPR
peak angular position values were above the baseline levels at
the end of the poloxamer desorption process, it was concluded
that the desorbed fraction of the poloxamer molecules were
incompletely attached to the surfaces or were only entangled
with other poloxamer molecules. The dendrimers did not
desorb from the surfaces, which indicates that a steady-state
SPR peak angular position in the adsorption phase was reached
due to surface saturation. For each sample, the adsorption onto
the indomethacin surface was slower than onto the plain gold
surface. Moreover, the poloxamer sample was the fastest and
the 3,4,5-G4 sample the slowest to reach steady-state values
during SPR responses (Figure S7). Changes in SPR responses
arise when the molecules in the aqueous phase are adsorbed
onto the sensor and cause refractive index changes near the
surface. In detail, the binding events are converted to a change
in the measurable sensor output value at eﬃciency, which
depends on the recognition element and the analyzed
compound. Therefore, the magnitude of the SPR responses
should not be directly compared between chemically distinct
samples; however, as the 3,4,5-G4 has a structure related to
3,4-G4 and also showed slower adsorption kinetics, it is
postulated that the bulkier hydrophobic domain (3 alkyl tails
vs. 2 alkyl tails) sterically hinders the packing of 3,4,5-G4 on
the surfaces. The ideal features of a steric stabilizer in terms of
steric hindrance rely on the aﬃnity of the stabilizer to the
particle surface as well as to the dispersant.7 In addition,
polymeric steric stabilization does not usually destroy the
crystal structure of drug particles, unlike the action of
conventional small molecular weight surfactants, for example,
sodium dodecyl sulfate (SDS). The irreversible adsorption of
the JDs to the indomethacin surfaces corroborates the
hypothesis that the stabilization of drug particles occurs mainly
due to steric hindrance and not by decrease of the surface
tension in which little to no adsorption would take place.
Particle Size Stabilization. Next, the particle size
reduction and the stabilization of the indomethacin suspen-
sions were screened in the presence of dendrimers using DLS.
Four and 7 days after milling, the Z-average size of the
suspension milled in the presence of 3,4-G3 showed the largest
Z-average size values (8549 ± 2853 and 9346 ± 2481 nm,
respectively), which is a clear indication of aggregation. The Z-
average sizes of the suspensions with 3,4,5-G3 (2228 ± 631
and 2334 ± 161 nm), 3,4-G4 (1084 ± 128 and 1561 ± 659
nm), and 3,4,5-G4 (1983 ± 475 and 1937 ± 352 nm) were
noticeably smaller and mostly nonaggregated.
Indomethacin suspensions in aqueous dendrimer solutions
(samples) and dendrimers solutions alone (background
controls) were milled and monitored weekly over a four-
week period (Figures 5 and S8) to examine the stability of the
coated drug particles. In general, the samples showed larger Z-
average sizes than the background controls. Considering this
and the ratios of the sample components, the Z-average sizes of
the samples should mainly reﬂect the Z-average size of the
indomethacin crystals in the suspensions. A closer examination
of the results from indomethacin milled in the presence of 3,4-
G3 revealed that during the four-week period the measured Z-
average sizes showed large variations (3049 nm) and
considerably irregular developments (Figure 5A). In contrast,
the Z-average size of the indomethacin suspensions milled with
Figure 4. SPR angle data for 3,4-G4 (A,D), 3,4,5-G4 (B,E), and poloxamer (C,F) for measurements conducted on pure gold (A−C) and
indomethacin covered (D−F) SPR sensors. The association phases (the ﬁrst 15 min) preceded the dissociation phases (from 15 to 33.4 min). The
two diﬀerent curves in each panel are repeated measurements of the same system.
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3,4,5-G3, 3,4-G4, and 3,4,5-G4 (Figure 5B−D) varied less over
the four-week period, increasing 690, 283, and 259 nm,
respectively. For 3,4,5-G3, the comparatively high uniformity
and abundance of small JDs’ background structures in the
control measurements (Figure S8) raised a question regarding
the potential bias in the stability results, which is discussed
later in the text. Structure−activity comparisons between the
dendrimers with the 3,4-hydrophobic dendron (3,4-G3 and
3,4-G4) suggested that the G4 hydrophilic dendron is required
for particle stabilization. In conclusion, the 3,4-G3 showed the
weakest performance as a stabilizer, whereas repeatable and
stable indomethacin particles were obtained in the presence of
G4 JDs. The results demonstrate the potential of G4 JDs to
stabilize drugs in submicron suspensions at low dendrimer-to-
drug mass ratios.
Suspensions obtained through media milling are often
formulated as dry dosage forms. To obtain dosage forms
with enhanced dissolution behaviors, the reduced size of the
particles should be maintained through downstream process-
ing, dry storage, and subsequent redispersion. To study the
stabilizing performance of the dendrimers in this context, the
milled indomethacin suspensions were dried, and the particle
sizes were determined after redispersion (Figure 6). In the
presence of the dendrimers and poloxamer, the indomethacin
particles had a Z-average size ranging from about 1 to 4 μm
after drying and redispersion. In the absence of these materials,
indomethacin particles had a Z-average size of about 27 μm.
The best stabilizing performances were observed for G4 JDs. It
should also be noted that the dry state stabilizing performances
of the G3 JDs were as good as the stabilizing performance of
the poloxamer.
Saturation Solubility. To examine the solubilizing
potential of the dendrimers, solubilized indomethacin contents
were determined from aqueous solutions saturated with an
excess of the bulk drug (Table 1). The apparent solubility of
indomethacin was moderately increased in buﬀer solutions
supplemented with the dendrimers compared to the solubility
in plain buﬀer. The absorbance values of 3,4-G4 containing
saturation solubility samples at a 280 nm wavelength were
about 2% of the values expected based on the UV spectrum
recorded from the 3,4-G4 (Figure S5). This could indicate that
a majority of the dendrimers was adsorbed onto nondissolved,
bulk drug particles and then removed during ﬁltration.
Considering the absorbance values of the other samples at
280 nm, the same held true for the other dendrimers, including
3,4,5-G3 which formed background nanostructures in aqueous
solutions. The formation of background structures was not
considered when interpreting the results of the contact angle
measurements. The formation of self-associated nanostructures
might compete against 3,4,5-G3 adsorption on the surfaces of
an aqueous drop thereby reducing the ability of the dendrimer
to inﬂuence the contact angle. However, the lack of dissolved
3,4,5-G3 in the saturation solubility experiment supported the
initial interpretations of the contact angle data, and contra-
dicted the existence of the self-associated background
structures in the milled indomethacin suspensions stabilized
with 3,4,5-G3, thereby conﬁrming the particle size stabilizing
potential of the JDs.
The solubility of indomethacin in a plain pH 5.0 buﬀer was 1
order of magnitude lower than a value reported in the
literature55 but well in line with indomethacin solubility in
acidiﬁed water at RT,56 however, water solubility over 1 order
of magnitude higher (16 mg L−1) has also been suggested for
indomethacin.48 The variations in the values reported in the
literature might reﬂect the pH sensitivity of the solubility
determinations close to the pKa value of indomethacin (4.3),
57
the temperature dependence of indomethacin solubility,58 the
diﬀerences in the dissolution characteristics of indomethacin
polymorphs,59 and the eﬀects of the experimental method-
ologies.60
Dissolution Rate. The dissolution of indomethacin
reached 90% of the indomethacin contents within 3 min in
Figure 5. Development of the Z-average size (left axis, line) and PDI
(right axis, squares) of an aqueous (A) 3,4-G3, (B) 3,4,5-G3, (C) 3,4-
G4, and (D) 3,4,5-G4 solutions milled with indomethacin. Chemical
structures abbreviated with colored text.
Figure 6. Z-average size (left axis, colored area) and PDI (right axis,
black squares) after drying and redispersion of indomethacin
suspensions milled in the presence sample materials (n = 1).
Table 1. Solubility of Indomethacin and Absorbance at
280.0 nm Measured in 2 mL of 9 mM Acetate Buﬀer (pH
5.0) Supplemented with Indomethacin and the Solubilizing
Agents (n = 1)a
solubilizing agent UV spectroscopy results
Janus-dendrimer or
control
content
[mg mL−1]
indomethacin
solubility [μg L−1]
absorbance
[AAU]
3,4-G3 0.30 590.1 0.0175
3,4,5-G3 0.30 434.3 0.0104
3,4-G4 0.30 493.5 0.0134
3,4,5-G4 0.30 557.2 0.0170
poloxamer 0.75 541.8 0.0121
none N/A 401.4 0.0107
aAbbreviations: not applicable (N/A), arbitrary absorbance unit
(AAU).
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all samples milled in the presence of dendrimers and
poloxamer (Figure 7A−D), and the extent of dissolution in
these samples did not decrease over the measured period. In
contrast, the dissolution of indomethacin milled in water
reached only 30% of the indomethacin content within 3 min
and decreased to 22% at the end of the experiment. For further
comparison, bulk indomethacin (nonmilled drug powder)
reached 4% dissolution within the time frame of the
experiment. The extent of bulk indomethacin dissolution
agreed with the extent of dissolution expected at an
equilibrium state (roughly 10%). Conversely, the maximum
extent of dissolution observed for the negative control in the
dissolution experiment (30%) greatly exceeded the measured
saturation solubility.
The dissolution of indomethacin (Figure 7) co-occurred
with the disappearance of drug particles scattering light (Figure
S9). Scattering was not evident in the results of indomethacin
milled without any stabilizer or bulk indomethacin. For the
remainder of the milled indomethacin suspensions, the
recorded absorbance values at 400 nm were small and sloped
downward during the ﬁrst 3 min of the experiment. This
indicates that light scattering can be detected using this
method and that scattering should only slightly aﬀect the
intensity of the light transmitted through the samples at the
beginning of the experiment when a large number of particles
is present and a majority of the drug has not yet dissolved. In
general, the results indicate that milling enhances the
dissolution of indomethacin and that the dendrimers can
stabilize the indomethacin suspensions produced by milling.
The samples milled in the presence of 3,4-G3 and 3,4,5-G3
(Figure 7A,B) showed slightly slower dissolution rates
compared to the poloxamer control, whereas the samples
milled in the presence of 3,4-G4 and 3,4,5-G4 (Figure 7C,D)
showed dissolution rates comparable to the poloxamer control.
It is noteworthy that indomethacin particles stabilized with
3,4,5-G3 and 3,4,5-G4 had comparable Z-average sizes, but the
particles stabilized with 3,4,5-G4 reached 90% dissolution
faster than the particles stabilized with 3,4,5-G3. As both JDs
have 3,4,5-substituted hydrophobic dendrons and there might
be a bias in the 3,4,5-G3 size results, only a speculative
structure−activity comparison of the hydrophilic dendrons is
given at this stage. The 3,4,5-G3 has less hydrogen bond
donors and acceptors than 3,4,5-G4, which might lead to
slower kinetics in the coating desorption and a simultaneous
decrease in the dissolution of indomethacin. The average
extent of indomethacin dissolution in the samples containing
3,4-G3 did not reach as high percentage values as the samples
containing the other dendrimers (Figure 7). Also, the particles
persisted longer in the 3,4-G3-containing samples than in the
poloxamer control and the samples stabilized with the other
dendrimers (Figure S9). In order to maintain a steric barrier
that is able to minimize interparticle interactions to a level that
the attractive van der Waals forces are lower than the repulsive
steric forces, the stabilizing moiety needs to be suﬃciently long
and dense.3 The less dense hydroxyl-terminated bis-MPA
dendron of the G3 JDs is therefore less eﬃcient in promoting
steric stabilization as the G4 JDs, which have double the
hydroxyl-terminated bis-MPA groups. Therefore, a higher Z-
average size and polydispersity is observed for G3-stabilized
drug particles compared to the G4-stabilized ones (Figure 5),
as well as a lower eﬃciency in promoting drug dissolution
(Figure 7).
Solubility Enhancement. The reduction of particle size
during the media milling process increases the total surface
area of indomethacin and improves the rate of dissolution
according to the Noyes−Whitney equation. Moreover, size
reduction has also been shown to increase the surface speciﬁc
dissolution rate.61 The suggested mechanism relies on
interpreting the combined eﬀect of the particle size’s
dependent terms according to the Prandtl boundary layer
equation for ﬂat surfaces (eq S1), viz. dissolving boundary
layer length (L) and the velocity of the solvent in relation to
the dissolving surface (V), as the correlated reduction of the
hydrodynamic boundary layer thickness (hH) and the distance
of molecular diﬀusion in the dissolution process. According to
Keck and Müller,62 saturation solubility increases as the
equilibrium between dissolution and recrystallization shifts due
to increasing dissolution rates. Therefore, the enhanced
solubility of indomethacin in the negative control of the
dissolution experiment is the result of size reduction (Figure
6). For the other samples in the dissolution experiment, the
observed enhancement of solubility may be due to the
combined eﬀect of the size reduction and the presence of
solubilizing and wetting agents.52,58 As previously noted, the
contact angles between aqueous dendrimer solutions and
indomethacin surfaces were relatively high, which indicates
that the dendrimers do not inﬂuence the wetting of
indomethacin. Moreover, assuming a constant ratio between
the amounts of the solubilizing agent and the increments in the
solubilized indomethacin content (Table 1), the size reduction
seems to largely dictate the extent of solubility enhancement.
Enhanced solubility is maintained in the stabilized
indomethacin suspensions with broad particle size distribu-
tions, especially in samples containing 3,4-G3 (Figures 5A and
7A). This may be explained by applying a polymeric net crystal
growth inhibition model, which relies on the Kelvin equation,
to the dendrimer coated drug crystals in the suspensions.63 In
essence, even a partial coverage of the seed crystal surfaces is
enough to inhibit crystal growth. According to the rationale
presented, the size reduction also enhances the dissolution rate
of the dendritic coatings on size-reduced particles with high
surface curvatures. Hence, while the coatings and the drug
molecules of the small particles dissolve rapidly, the coatings of
the larger particles should persist longer and should slow the
Figure 7. Dissolution results of (A) 3,4-G3, (B) 3,4,5-G3, (C) 3,4-G4,
and (D) 3,4,5-G4 samples (colored circles), the poloxamer control
(light gray squares), negative control (gray squares ± gray area) and
bulk drug (black squares) as measured at 318.5 nm wavelength (n =
3). The asterisk represents signiﬁcant diﬀerences between the sample
and the poloxamer control (p = 0.05). Chemical structures
abbreviated with colored text.
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recrystallization of indomethacin. An apparent lack of
recrystallization might also be caused by the slow kinetics of
indomethacin recrystallization,64 however the slow indome-
thacin recrystallization in the stabilized samples reﬂects a
shortage of noncoated seed crystal facets in the dissolution
media, as the extent of dissolution sloped downward in the
negative control but not in the stabilized suspensions during
the dissolution experiment.
4. CONCLUSIONS
High-generation amphiphilic JDs (G3 and G4) obtained via a
copper-catalyzed click-chemistry reaction using a modular
synthesis approach were used to screen submicron drug crystal
stabilization. The screening methodology applied minimizes
the use of stabilizing materials, and the results demonstrate a
good applicability of the G4 JDs as stabilizers in media milling
and the subsequent dry-state processing of pharmaceuticals.
The dense steric layer induced by the hydroxyl terminated bis-
MPA dendrons in the G4 JDs plays a critical role in the
stabilization process preventing the drug particles’ agglomer-
ation for extended periods of time, while enabling low
polydispersity values when compared with G3 JDs and
Poloxamer 188. Further, the SPR measurements support the
hypothesis that JDs irreversibly adsorb onto the indomethacin
surfaces via hydrophobic interactions and that the number of
hydrophobic alkyl tails determine the adsorption kinetics of the
JDs. In addition, both G4 JDs increase the drug dissolution
rate of poorly water-soluble compounds to the same extent as
the poloxamer at a lower stabilizer-to-drug ratio. We thus
believe that the modular synthesis approach for JDs described
here oﬀers a convenient and eﬃcient route for the stabilization
of poorly water-soluble drugs in suspension. As a result, we
envisage that these structures may be further tailored and
scaled-up for pharmaceutical processing purposes.
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S. E.; Vetro, M.; Veŕtesy, S.; Kaltner, H.; Reed, E. H.; Möller, M.;
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